Do you want to read an article? Please log in or register.
Neoantigen prediction and computational perspectives towards clinical benefit: Recommendations from the ESMO Precision Medicine Working Group
Further Publications
Related content
Further Publications
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group
Ann Oncol.
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho J, Dienstmann R, André F
doi: 10.1016/j.annonc.2020.07.014.
RECOMMENDED
Gynecologic Cancer
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol.
Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR
doi: 10.1016/j.annonc.2020.08.2102.
Breast Cancer
Breast Cancer Treatment in the Era of Precision Medicine
1Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
Multiple Myeloma (MM)
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
Lancet Oncol
Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N, Bone Working Group of the International Myeloma Working Group.
doi: 10.1016/S1470-2045(20)30559-3
Further Publications
Clinical Application of Computational Methods in Precision Oncology: A Review
JAMA Oncol.
Panagiotou OA, Högg LH, Hricak H, Khleif SN, Levy MA, Magnus D, Murphy MJ, Patel B, Winn RA, Nass SJ, Gatsonis C, Cogle CR
doi: 10.1001/jamaoncol.2020.1247.
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Further Publications
Precision Oncology and Gender Medicine – Moving Forward, Slowly but Surely
healthbook TIMES Oncology Hematology
1Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), CH-1011, Switzerland
2International Cancer Prevention Institute, Epalinges, CH-1066, Switzerland
*corresponding authors
Gastrointestinal CancerFurther Publications
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020
★ 3
Recommended and commented by
Alexander Meisel, Faculty Member
healthbook TIMES Oncology Hematology
Corresponding author:
Dr Alexander Siebenhüner
Senior Consultant in Medical Oncology
Cantonal Hospital Schaffhausen
Schaffhausen, Switzerland
Further Publications
Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers: State of the Art and Future Directions
★ 3
Recommended and commented by
Alexander Meisel, Faculty Member
1Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
*equal contribution